Trulicity (Dulaglutide) vs Ozempic: Weight Loss, A1C, and Dosing Compared [2026]

Trulicity (dulaglutide) and Ozempic (semaglutide) are both once-weekly GLP-1 receptor agonists approved to treat type 2 diabetes, and they get compared constantly because they sit on the same pharmacy shelf and do similar jobs. But the head-to-head trial data tell a clear story: in the one study that pitted them directly against each other, semaglutide lowered blood sugar more and dropped more weight. This guide walks through what the actual evidence shows on A1C, weight, heart protection, dosing, side effects, and cost, and where the data are strong versus thin.

The Short Version of the Evidence

The two drugs are close cousins. Both are injected under the skin once a week. Both mimic the gut hormone GLP-1, which tells your pancreas to release insulin when blood sugar is high, slows how fast your stomach empties, and reduces appetite. Both have a proven track record of cutting the risk of heart attack and stroke in people with type 2 diabetes.

The single most important fact is that they were tested directly against each other in one large trial called SUSTAIN 7. Most "drug vs drug" comparisons rely on guesswork because the two drugs were never studied side by side. That is not the case here. SUSTAIN 7 randomized over 1,200 people and gave a clean answer.

Where it gets murkier is weight loss. Neither Trulicity nor Ozempic is FDA-approved for weight loss. Any pounds lost are a side effect of treating diabetes, not the labeled purpose. That distinction matters for insurance, dosing, and what you should reasonably expect.

How Each Drug Works

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It does several things at once. It nudges the pancreas to make more insulin, but only when blood sugar is elevated, which is why these drugs rarely cause dangerous low blood sugar on their own. It tells the liver to release less stored sugar. It slows stomach emptying, so food sits longer and you feel full. And it acts on the brain's appetite centers to dial down hunger.

Both dulaglutide and semaglutide are engineered versions of this hormone built to last a full week in the body instead of minutes. The molecular tricks they use to survive that long differ, but the end result is similar: one weekly shot, steady hormone levels.

The one mechanistic difference worth knowing is potency. In the body, semaglutide tends to produce a stronger overall GLP-1 effect at its approved doses. That shows up in the trial numbers, not just on paper.

SUSTAIN 7: The Head-to-Head Trial

SUSTAIN 7 is the centerpiece of any honest comparison. It was a 40-week, open-label, phase 3b trial run at 194 sites across 16 countries. Researchers enrolled 1,201 adults with type 2 diabetes whose blood sugar was not controlled on metformin alone, with starting A1C between 7.0% and 10.5%. They were split into four groups and matched by dose strength: low-dose semaglutide (0.5 mg) against low-dose dulaglutide (0.75 mg), and high-dose semaglutide (1.0 mg) against high-dose dulaglutide (1.5 mg).

The trial was "open-label," meaning patients and doctors knew which drug was being used. That is a real limitation. Knowing you are on the "stronger" drug can color how you report side effects or how hard you try with diet. The blood sugar and weight measurements themselves are objective, so the core findings hold up, but it is worth keeping in mind.

A1C Results

A1C is a blood test that reflects your average blood sugar over about three months. Lower is better; under 7% is a common target for many adults with diabetes. In every matched comparison, semaglutide won.

Comparison (vs metformin background)	A1C reduction	Reached A1C under 7%
Semaglutide 0.5 mg	−1.5%	~68%
Dulaglutide 0.75 mg	−1.1%	~52%
Semaglutide 1.0 mg	−1.8%	~79%
Dulaglutide 1.5 mg	−1.4%	~67%

The gap of roughly 0.3 to 0.4 percentage points is small-sounding but clinically real. More people hit their target on semaglutide at both dose levels. These numbers come straight from the published SUSTAIN 7 results.

Weight Results

This is where the difference is most visible. At the time of SUSTAIN 7, dulaglutide topped out at 1.5 mg, so the comparison reflects the doses available then.

Drug and dose	Average weight loss at 40 weeks	Lost at least 5% of body weight
Semaglutide 0.5 mg	~4.6 kg (~10 lb)	~44%
Dulaglutide 0.75 mg	~2.3 kg (~5 lb)	~23%
Semaglutide 1.0 mg	~6.5 kg (~14 lb)	~63%
Dulaglutide 1.5 mg	~3.0 kg (~7 lb)	~30%

Semaglutide produced roughly twice the weight loss at matched dose levels. That is a large, consistent difference. If weight is a major concern, the evidence points one direction.

The honest caveat: dulaglutide now comes in higher doses (3.0 mg and 4.5 mg) that did not exist when SUSTAIN 7 ran. Those higher doses lose more weight than 1.5 mg, but they have never been tested head-to-head against semaglutide. More on that next.

The Higher-Dose Dulaglutide Question

In 2020, the FDA approved two larger doses of Trulicity: 3.0 mg and 4.5 mg. The trial behind that approval was AWARD-11, which compared dulaglutide 1.5 mg, 3.0 mg, and 4.5 mg in over 1,800 people on metformin.

Dulaglutide dose	A1C reduction at week 36	Weight loss at week 36
1.5 mg	−1.5%	~3.0 kg
3.0 mg	−1.6%	~3.8 kg
4.5 mg	−1.8%	~4.6 kg

Two things stand out. First, the higher doses do help, but the gains are modest. Going from 1.5 mg to 4.5 mg, three times the drug, bought roughly 0.3% more A1C reduction and about 1.6 kg more weight loss. Second, even the top dose of dulaglutide (4.5 mg, −1.8% A1C, −4.6 kg) roughly matches what semaglutide achieved at its 1.0 mg dose in SUSTAIN 7, and Ozempic now goes up to 2.0 mg.

So the higher Trulicity doses narrow the gap but, based on cross-trial comparison, probably do not close it. The key word is "cross-trial." Comparing results from two separate studies is unreliable because the patient groups, sites, and conditions differ. We genuinely do not have a head-to-head trial of dulaglutide 4.5 mg against semaglutide 2.0 mg. Anyone who tells you with certainty which is stronger at top dose is going beyond the evidence. Grade that claim as "probably semaglutide, but unproven."

Dosing and Titration

Both drugs start low and step up over weeks to let your gut adjust. This is the single biggest factor in how well you tolerate them. Rushing the dose increase is the most common reason people quit.

	Trulicity (dulaglutide)	Ozempic (semaglutide)
Starting dose	0.75 mg weekly	0.25 mg weekly (first 4 weeks)
Common maintenance	1.5 mg weekly	0.5 mg or 1.0 mg weekly
Maximum dose	4.5 mg weekly	2.0 mg weekly
Step-up interval	At least 4 weeks per step	At least 4 weeks per step
Injection	Pre-filled auto-pen, no priming, no needle to see	Multi-dose pen, needle attached each time
Mixing or prep	None	None

One practical edge for Trulicity: the auto-injector hides the needle entirely and requires no dose dialing. For needle-shy people, that is a genuine plus. Ozempic uses a multi-dose pen where you attach a needle and dial the dose. Neither is hard, but the Trulicity device is simpler. For a deeper walkthrough of semaglutide titration, see our semaglutide dosing schedule guide.

Heart Protection: Both Have It

This is one of the strongest areas of evidence for both drugs, and it is a tie in terms of "yes, it works," though the trials were different.

Dulaglutide was tested in REWIND, a placebo-controlled trial of 9,901 people followed for a median of 5.4 years. It cut the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 12% (hazard ratio 0.88). What made REWIND notable is that most participants did not already have heart disease; the majority had risk factors but no prior event. That suggests dulaglutide may help with primary prevention, not just in people who already had a heart attack.

Semaglutide was tested in SUSTAIN 6, a placebo-controlled trial of 3,297 higher-risk people followed for about two years. It cut major cardiovascular events by 26% (hazard ratio 0.74). That looks like a bigger number than dulaglutide's, but the comparison is unfair: SUSTAIN 6 enrolled sicker patients over a shorter time and was designed mainly to prove safety, not to measure benefit precisely. You cannot conclude semaglutide is "twice as protective." Both drugs carry an FDA indication to reduce cardiovascular events in adults with type 2 diabetes and heart disease or risk factors. Grade: strong evidence for both, no proven winner.

One safety signal from SUSTAIN 6 deserves a flag: a higher rate of worsening diabetic retinopathy (eye damage) in the semaglutide group, thought to be linked to rapid blood sugar drops. If you have existing retinopathy, your doctor should monitor your eyes when starting or escalating semaglutide.

How Strong Is the Evidence, Really?

It helps to grade the claims rather than treat them all as equally solid.

Claim	Evidence quality	Honest read
Semaglutide beats dulaglutide on A1C and weight at matched doses	High (direct head-to-head RCT)	Solid. SUSTAIN 7 is a real comparison, not guesswork.
The advantage holds at top doses (sema 2.0 vs dula 4.5)	Low (cross-trial only)	Plausible but unproven. No head-to-head exists.
Both drugs reduce cardiovascular events	High (two large RCTs)	Solid for both, separately proven.
Semaglutide protects the heart more than dulaglutide	Very low	Not supported. Different trials, different patients.
One drug is better tolerated than the other	Low	No clear winner; varies by person.

The single weakest spot in the popular "Ozempic crushes Trulicity" narrative is the top-dose comparison. People cite SUSTAIN 7 (which used old, low dulaglutide doses) and then assume the gap is permanent. It might not be. Treat that as an open question.

Kidneys, Older Adults, and Other Special Cases

Both drugs are relatively kidney-friendly, which matters because diabetes is the leading cause of kidney disease. Neither requires a dose change for reduced kidney function, including in severe cases. That sets them apart from some older diabetes drugs that build up when kidneys fail. The main kidney risk is indirect: if heavy nausea causes vomiting and dehydration, kidney function can dip, so staying hydrated during dose increases is important.

In older adults, both work, but two cautions apply to either drug. Appetite suppression plus muscle loss can be a problem in frail patients, so weight loss is not always the goal. And combining a GLP-1 with insulin or a sulfonylurea raises low-blood-sugar risk, which is more dangerous in older people; those background medications often need to be reduced first.

Side Effects and Safety

The side effect profiles are very similar because the drugs work the same way. The dominant issue for both is the gut.

In SUSTAIN 7, gastrointestinal side effects were the most common problem and the leading cause of people quitting. Nausea, diarrhea, vomiting, and constipation showed up in roughly 33% to 48% of people across the groups, with broadly similar rates between the two drugs. There is no clear tolerability winner; both cause meaningful nausea, especially during dose increases. Most of it fades after the first few weeks if you titrate slowly and eat smaller, lower-fat meals.

Both drugs share the same warnings:

Thyroid tumor boxed warning. Both cause thyroid C-cell tumors in rodents. Whether this happens in humans is unknown. Both are contraindicated if you or a close relative has medullary thyroid cancer or the genetic syndrome MEN 2.
Pancreatitis. Rare but serious. Stop the drug and call your doctor for severe, persistent stomach pain.
Gallbladder problems. Gallstones and gallbladder inflammation occur more often, partly tied to rapid weight loss.
Low blood sugar. Uncommon alone, but the risk rises sharply if combined with insulin or sulfonylureas, which may need dose reduction.
Kidney effects from dehydration. Heavy vomiting or diarrhea can stress the kidneys.

For the full semaglutide-specific side effect picture, see our Ozempic side effects 2026 review. One nuance: faster, larger weight loss with semaglutide can mean more noticeable facial fat loss, sometimes called "Ozempic face," which is really just a feature of rapid weight reduction rather than a unique drug effect.

Cost and Access

Both are brand-name drugs with no generic version, so list prices run high, often more than $900 to $1,000 a month before insurance. What you actually pay depends almost entirely on your coverage.

A few practical points. Insurance typically covers either drug only for type 2 diabetes, not for weight loss, since neither is approved for weight management. Manufacturer savings cards from Eli Lilly (Trulicity) and Novo Nordisk (Ozempic) can cut copays for commercially insured patients, but they are blocked for people on Medicare or Medicaid. Supply has been less of a problem than during the worst shortage years, but availability still varies by pharmacy and dose. Price-wise, the two are usually in the same ballpark; neither is reliably cheaper, so check your specific plan's formulary rather than assuming.

There is also the real-world adherence angle, which trials understate. In a controlled study, everyone gets reminders and free drugs. In real life, people stop GLP-1s often, mostly because of cost, side effects, or simply forgetting the weekly shot. A medication you actually keep taking beats a slightly stronger one you quit. That is part of why the simpler Trulicity device is not a trivial consideration; ease of use feeds adherence, and adherence drives results. If side effects or device hassle would make you skip doses, the "weaker on paper" option can win in practice.

Who Each Drug Fits

There is no universal "better" drug here, only better fits.

Trulicity may fit you if you want the simplest possible injection (the no-needle-visible auto-pen), your main goal is solid A1C control rather than maximum weight loss, you value a heart-protection trial that included people without established heart disease, or you simply tolerate it better. Some people get more nausea on one drug than the other, and that is hard to predict in advance.

Ozempic may fit you if weight loss is a high priority alongside blood sugar control, you want the larger average A1C reduction shown in the head-to-head trial, or you have not reached your target on another GLP-1. The trade-off is a slightly more involved pen and the retinopathy caution if you already have eye disease.

For both, the decision should run through your doctor and your insurance formulary, because coverage often decides the matter before clinical preference does. If you are weighing GLP-1 options more broadly, our Wegovy vs Ozempic comparison covers the semaglutide weight-loss version, and our Mounjaro vs Ozempic head-to-head and semaglutide vs tirzepatide comparison cover the newer dual-hormone drugs that now outperform both Trulicity and Ozempic on weight.

The Bottom Line

In the only head-to-head trial, semaglutide beat dulaglutide on both blood sugar and weight at matched doses, and that advantage is real and consistently measured. Higher-dose Trulicity narrows the gap but has never been tested directly against high-dose Ozempic, so the top-dose comparison stays unproven. Both drugs strongly protect the heart, both hit the gut with similar side effects, and both cost about the same. For raw efficacy the evidence favors Ozempic; for injection simplicity and broader heart-prevention data, Trulicity holds its ground.

Frequently Asked Questions

Is Ozempic better than Trulicity for weight loss?

In the SUSTAIN 7 head-to-head trial, semaglutide produced about twice the weight loss of dulaglutide at matched doses. That said, neither drug is FDA-approved for weight loss, and Trulicity's newer higher doses (not tested against Ozempic) lose more than its old dose. For raw weight loss the evidence favors Ozempic, but the gap at top doses is unproven.

Can I switch from Trulicity to Ozempic?

Many people do switch, usually for better A1C control or more weight loss. Your doctor will typically start you at Ozempic's low 0.25 mg dose and step up over weeks, even if you were on a higher equivalent Trulicity dose, to limit nausea. Do not switch on your own; the titration schedule matters for tolerability.

Do Trulicity and Ozempic both protect the heart?

Yes. Dulaglutide cut major cardiovascular events by 12% in the REWIND trial, and semaglutide cut them by 26% in SUSTAIN 6. The trials used different patients and lengths, so you cannot fairly conclude one is more protective. Both carry an FDA indication to reduce heart attack and stroke risk in adults with type 2 diabetes and heart disease or risk factors.

Which has worse side effects, Trulicity or Ozempic?

They are very similar. Both cause nausea, diarrhea, vomiting, and constipation in roughly a third to nearly half of users, mostly during dose increases. SUSTAIN 7 did not show a clear tolerability winner. Individual response varies, so some people feel better on one than the other, and that is hard to predict before trying.

Is Trulicity cheaper than Ozempic?

Usually not by much. Both are brand-name drugs with no generic, often listing above $900 a month before insurance. Your real cost depends on your plan's formulary and manufacturer savings cards, which work for commercial insurance but not Medicare or Medicaid. Check your specific coverage rather than assuming one is cheaper.

This article is for general education and is not medical advice. Talk to your doctor or pharmacist before starting, stopping, or switching any GLP-1 medication.